Symbols / TECX Stock $27.80 -2.46% Tectonic Therapeutic, Inc.
TECX (Stock) Chart
About
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Stock Fundamentals
Scroll to Statements| Market Cap | 521.99M | Enterprise Value | 282.61M | Income | -74.15M | Sales | — | Book/sh | 13.41 | Cash/sh | 13.52 |
| Dividend Yield | — | Payout | 0.00% | Employees | 60 | IPO | — | P/E | — | Forward P/E | -5.94 |
| PEG | — | P/S | — | P/B | 2.07 | P/C | — | EV/EBITDA | -3.42 | EV/Sales | — |
| Quick Ratio | 26.26 | Current Ratio | 26.62 | Debt/Eq | 0.51 | LT Debt/Eq | — | EPS (ttm) | -4.05 | EPS next Y | -4.68 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-07 | ROA | -25.38% | ROE | -37.82% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 18.78M | Shs Float | 11.18M | Short Float | 22.56% |
| Short Ratio | 7.54 | Short Interest | — | 52W High | 36.03 | 52W Low | 14.39 | Beta | — | Avg Volume | 370.54K |
| Volume | 53.11K | Target Price | $77.89 | Recom | Strong_buy | Prev Close | $28.50 | Price | $27.80 | Change | -2.46% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-14 | init | Stifel | — → Buy | $75 |
| 2026-01-08 | main | Truist Securities | Buy → Buy | $60 |
| 2025-09-03 | init | Oppenheimer | — → Outperform | $80 |
| 2025-07-21 | init | Truist Securities | — → Buy | $64 |
| 2025-06-06 | init | LifeSci Capital | — → Outperform | $87 |
| 2025-05-15 | main | Mizuho | Outperform → Outperform | $85 |
| 2025-04-21 | init | Mizuho | — → Outperform | $51 |
| 2025-03-21 | main | Wells Fargo | Overweight → Overweight | $101 |
| 2025-01-31 | main | Wells Fargo | Overweight → Overweight | $112 |
| 2024-11-20 | init | Raymond James | — → Outperform | $65 |
| 2024-11-12 | main | Wells Fargo | Overweight → Overweight | $79 |
| 2024-11-11 | main | Leerink Partners | Outperform → Outperform | $69 |
| 2024-08-22 | init | Wells Fargo | — → Overweight | $55 |
| 2024-07-24 | init | Leerink Partners | — → Outperform | $49 |
| 2024-06-26 | init | Piper Sandler | — → Overweight | $76 |
| 2024-06-24 | init | TD Cowen | — → Buy | — |
- TECX (Tectonic Therapeutic Inc.) posts narrower Q4 2025 loss than analyst estimates, but shares dip nearly one percent today. - Real Trader Insights - UBND thành phố Hải Phòng Wed, 22 Apr 2026 20
- $TECX stock is up 19% today. Here's what we see in our data. - Quiver Quantitative Fri, 06 Mar 2026 08
- MSN Money - MSN Wed, 22 Apr 2026 11
- Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2 - Seeking Alpha hu, 16 Apr 2026 11
- Director at Tectonic Therapeutic (TECX) awarded 20,400 stock options at $30.78 - Stock Titan Fri, 03 Apr 2026 07
- Tectonic Therapeutic, Inc. Common Stock (TECX) Stock Price Today & Analysis - Gotrade Wed, 18 Feb 2026 20
- Insiders In Tectonic Therapeutic Still Down 37% On US$51.1m Investment - simplywall.st ue, 03 Feb 2026 08
- Is Tectonic Therapeutic (TECX) Stock Testing Support | Price at $30.25, Down 0.88% - MA Crossover - Cổng thông tin điện tử Tỉnh Sơn La Mon, 06 Apr 2026 07
- Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance Sat, 22 Nov 2025 08
- Moderna board veteran François Nader to lead Tectonic Therapeutic - Stock Titan Mon, 23 Feb 2026 08
- Insider Purchase: Chief Executive Officer of $TECX Buys 2,500 Shares - Quiver Quantitative hu, 12 Feb 2026 08
- Tectonic Therapeutic (TECX) CMO sells 1,000 shares in planned trade - Stock Titan Fri, 03 Apr 2026 07
- Biotech Tectonic to hold March investor fireside chats and one-on-one meetings - Stock Titan Mon, 02 Mar 2026 08
- TECX SEC Filings - Tectonic Therapeutic Inc 10-K, 10-Q, 8-K Forms - Stock Titan Sun, 29 Mar 2026 16
- Tectonic Therapeutic (TECX) director Nader Francois files initial Form 3 - Stock Titan Fri, 03 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
84.04
+44.85%
|
58.02
+29.94%
|
44.65
+36.00%
|
32.83
|
| Research And Development |
|
63.49
+53.49%
|
41.36
+11.90%
|
36.97
+44.09%
|
25.65
|
| Selling General And Administration |
|
20.55
+23.40%
|
16.65
+116.75%
|
7.68
+7.05%
|
7.18
|
| General And Administrative Expense |
|
20.55
+23.40%
|
16.65
+116.75%
|
7.68
+7.05%
|
7.18
|
| Salaries And Wages |
|
11.55
+46.91%
|
7.86
+99.34%
|
3.94
+0.18%
|
3.94
|
| Other Gand A |
|
9.00
+2.37%
|
8.79
+135.13%
|
3.74
+15.41%
|
3.24
|
| Total Expenses |
|
84.04
+44.85%
|
58.02
+29.94%
|
44.65
+36.00%
|
32.83
|
| Operating Income |
|
-84.04
-44.85%
|
-58.02
-29.94%
|
-44.65
-36.00%
|
-32.83
|
| Total Operating Income As Reported |
|
-84.04
-44.85%
|
-58.02
-29.94%
|
-44.65
-36.00%
|
-32.83
|
| EBITDA |
|
-71.48
-27.13%
|
-56.23
-36.50%
|
-41.19
-32.75%
|
-31.03
|
| Normalized EBITDA |
|
-71.48
-35.85%
|
-52.62
-23.96%
|
-42.45
-34.02%
|
-31.67
|
| Reconciled Depreciation |
|
1.38
-16.41%
|
1.65
+11.30%
|
1.48
+46.92%
|
1.01
|
| EBIT |
|
-72.86
-25.89%
|
-57.88
-35.63%
|
-42.67
-33.20%
|
-32.04
|
| Total Unusual Items |
|
—
|
-3.61
-387.65%
|
1.25
+95.18%
|
0.64
|
| Total Unusual Items Excluding Goodwill |
|
—
|
-3.61
-387.65%
|
1.25
+95.18%
|
0.64
|
| Net Income |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Pretax Income |
|
-72.92
-25.76%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Net Non Operating Interest Income Expense |
|
11.23
+170.44%
|
4.15
+868.30%
|
0.43
+8480.00%
|
0.01
|
| Interest Expense Non Operating |
|
0.06
-41.12%
|
0.11
-29.61%
|
0.15
+5.56%
|
0.14
|
| Net Interest Income |
|
11.23
+170.44%
|
4.15
+868.30%
|
0.43
+8480.00%
|
0.01
|
| Interest Expense |
|
0.06
-41.12%
|
0.11
-29.61%
|
0.15
+5.56%
|
0.14
|
| Interest Income Non Operating |
|
11.30
+165.13%
|
4.26
+633.39%
|
0.58
+289.93%
|
0.15
|
| Interest Income |
|
11.30
+165.13%
|
4.26
+633.39%
|
0.58
+289.93%
|
0.15
|
| Other Income Expense |
|
-0.12
+97.11%
|
-4.12
-395.20%
|
1.40
+116.43%
|
0.65
|
| Other Non Operating Income Expenses |
|
-0.12
+76.71%
|
-0.51
-462.41%
|
0.14
+6950.00%
|
0.00
|
| Gain On Sale Of Security |
|
—
|
-3.61
-387.65%
|
1.25
+95.18%
|
0.64
|
| Tax Provision |
|
1.23
|
0.00
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Net Income From Continuing Operation Net Minority Interest |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Net Income From Continuing And Discontinued Operation |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Net Income Continuous Operations |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Normalized Income |
|
-74.15
-36.38%
|
-54.37
-23.35%
|
-44.08
-34.29%
|
-32.82
|
| Net Income Common Stockholders |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Diluted EPS |
|
—
|
-6.83
-135.00%
|
-2.91
-33.07%
|
-2.18
|
| Basic EPS |
|
—
|
-6.83
-135.00%
|
-2.91
-33.07%
|
-2.18
|
| Basic Average Shares |
|
—
|
8.49
-42.38%
|
14.73
+0.00%
|
14.73
|
| Diluted Average Shares |
|
—
|
8.49
-42.38%
|
14.73
+0.00%
|
14.73
|
| Diluted NI Availto Com Stockholders |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
261.04
+70.72%
|
152.91
+288.09%
|
39.40
-16.54%
|
47.21
|
| Current Assets |
|
257.36
+75.24%
|
146.86
+375.51%
|
30.88
-16.62%
|
37.04
|
| Cash Cash Equivalents And Short Term Investments |
|
253.80
+79.69%
|
141.24
+390.94%
|
28.77
-20.01%
|
35.97
|
| Cash And Cash Equivalents |
|
253.80
+79.69%
|
141.24
+390.94%
|
28.77
-20.01%
|
35.97
|
| Restricted Cash |
|
0.59
|
0.00
|
—
|
—
|
| Other Current Assets |
|
2.97
-47.06%
|
5.62
+165.63%
|
2.12
+96.56%
|
1.08
|
| Total Non Current Assets |
|
3.68
-39.17%
|
6.05
-28.97%
|
8.52
-16.25%
|
10.17
|
| Net PPE |
|
2.55
-51.86%
|
5.30
-26.60%
|
7.23
-24.35%
|
9.55
|
| Gross PPE |
|
5.96
-25.95%
|
8.05
-11.38%
|
9.08
-12.91%
|
10.43
|
| Accumulated Depreciation |
|
-3.41
-24.12%
|
-2.75
-47.90%
|
-1.86
-111.63%
|
-0.88
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.28
+0.00%
|
0.28
-30.62%
|
0.41
+3.05%
|
0.39
|
| Construction In Progress |
|
—
|
0.00
-100.00%
|
0.04
-22.45%
|
0.05
|
| Other Properties |
|
5.66
-26.98%
|
7.74
-10.12%
|
8.62
-13.53%
|
9.96
|
| Leases |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Non Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.67
|
—
|
| Other Non Current Assets |
|
1.12
+51.41%
|
0.74
+20.23%
|
0.62
+0.82%
|
0.61
|
| Total Liabilities Net Minority Interest |
|
9.71
-19.95%
|
12.13
-90.22%
|
124.03
+33.57%
|
92.86
|
| Current Liabilities |
|
9.67
-16.74%
|
11.61
-71.61%
|
40.89
+421.73%
|
7.84
|
| Payables And Accrued Expenses |
|
4.32
-17.52%
|
5.24
-7.96%
|
5.69
+52.61%
|
3.73
|
| Payables |
|
1.09
+11.99%
|
0.98
+138.63%
|
0.41
-28.75%
|
0.57
|
| Accounts Payable |
|
1.09
+11.99%
|
0.98
+138.63%
|
0.41
-28.75%
|
0.57
|
| Current Accrued Expenses |
|
3.23
-24.27%
|
4.26
-19.30%
|
5.29
+67.41%
|
3.16
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.11
+14.64%
|
3.58
+25.53%
|
2.86
+32.34%
|
2.16
|
| Current Debt And Capital Lease Obligation |
|
1.23
-55.71%
|
2.78
+52.72%
|
1.82
+25.81%
|
1.45
|
| Current Capital Lease Obligation |
|
1.23
-55.71%
|
2.78
+52.72%
|
1.82
+25.81%
|
1.45
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Other Current Liabilities |
|
—
|
—
|
30.52
+6015.23%
|
0.50
|
| Total Non Current Liabilities Net Minority Interest |
|
0.04
-91.71%
|
0.52
-99.38%
|
83.15
-2.21%
|
85.03
|
| Long Term Debt And Capital Lease Obligation |
|
0.04
-91.71%
|
0.52
-79.40%
|
2.52
-41.98%
|
4.34
|
| Long Term Capital Lease Obligation |
|
0.04
-91.71%
|
0.52
-79.40%
|
2.52
-41.98%
|
4.34
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
0.06
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
80.63
+0.00%
|
80.63
|
| Stockholders Equity |
|
251.33
+78.53%
|
140.78
+266.33%
|
-84.64
-85.39%
|
-45.65
|
| Common Stock Equity |
|
251.33
+78.53%
|
140.78
+266.33%
|
-84.64
-85.39%
|
-45.65
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
—
|
| Share Issued |
|
18.74
+26.13%
|
14.86
+0.83%
|
14.73
+0.00%
|
14.73
|
| Ordinary Shares Number |
|
18.74
+26.13%
|
14.86
+0.83%
|
14.73
+0.00%
|
14.73
|
| Additional Paid In Capital |
|
474.16
+63.87%
|
289.35
+4739.45%
|
5.98
+181.10%
|
2.13
|
| Retained Earnings |
|
-222.74
-49.90%
|
-148.59
-63.99%
|
-90.60
-89.62%
|
-47.78
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.10
-1166.67%
|
0.01
+181.82%
|
-0.01
|
—
|
| Other Equity Adjustments |
|
-0.10
-1166.67%
|
0.01
+181.82%
|
-0.01
|
—
|
| Total Equity Gross Minority Interest |
|
251.33
+78.53%
|
140.78
+266.33%
|
-84.64
-85.39%
|
-45.65
|
| Total Capitalization |
|
251.33
+78.53%
|
140.78
+266.33%
|
-84.64
-85.39%
|
-45.65
|
| Working Capital |
|
247.69
+83.14%
|
135.25
+1451.93%
|
-10.00
-134.25%
|
29.20
|
| Invested Capital |
|
251.33
+78.53%
|
140.78
+266.33%
|
-84.64
-85.39%
|
-45.65
|
| Total Debt |
|
1.28
-61.37%
|
3.30
-23.95%
|
4.34
-25.02%
|
5.79
|
| Capital Lease Obligations |
|
1.28
-61.37%
|
3.30
-23.95%
|
4.34
-25.02%
|
5.79
|
| Net Tangible Assets |
|
251.33
+78.53%
|
140.78
+266.33%
|
-84.64
-85.39%
|
-45.65
|
| Tangible Book Value |
|
251.33
+78.53%
|
140.78
+266.33%
|
-84.64
-85.39%
|
-45.65
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-60.08
-1.69%
|
-59.08
-45.23%
|
-40.68
-47.20%
|
-27.64
|
| Cash Flow From Continuing Operating Activities |
|
-60.08
-1.69%
|
-59.08
-45.23%
|
-40.68
-47.20%
|
-27.64
|
| Net Income From Continuing Operations |
|
-74.15
-27.89%
|
-57.98
-35.40%
|
-42.82
-33.07%
|
-32.18
|
| Depreciation Amortization Depletion |
|
1.38
-16.41%
|
1.65
+11.30%
|
1.48
+46.92%
|
1.01
|
| Depreciation And Amortization |
|
1.38
-16.41%
|
1.65
+11.30%
|
1.48
+46.92%
|
1.01
|
| Other Non Cash Items |
|
2.12
-47.63%
|
4.04
+3051.82%
|
-0.14
-111.18%
|
1.23
|
| Stock Based Compensation |
|
10.50
+200.69%
|
3.49
+211.42%
|
1.12
+0.18%
|
1.12
|
| Operating Gains Losses |
|
0.15
|
—
|
0.26
+141.06%
|
-0.64
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.64
|
| Gain Loss On Sale Of PPE |
|
0.15
|
0.00
-100.00%
|
0.01
|
—
|
| Change In Working Capital |
|
-0.07
+99.32%
|
-10.28
-1659.93%
|
-0.58
-131.81%
|
1.84
|
| Change In Prepaid Assets |
|
2.64
+182.78%
|
-3.19
-213.44%
|
-1.02
-171.01%
|
-0.38
|
| Change In Payables And Accrued Expense |
|
-0.44
+93.83%
|
-7.06
-588.45%
|
1.45
-55.85%
|
3.27
|
| Change In Accrued Expense |
|
-0.55
+90.22%
|
-5.64
-450.22%
|
1.61
-64.27%
|
4.51
|
| Change In Payable |
|
0.12
+108.16%
|
-1.42
-761.21%
|
-0.17
+86.63%
|
-1.23
|
| Change In Account Payable |
|
0.12
+108.16%
|
-1.42
-761.21%
|
-0.17
+86.63%
|
-1.23
|
| Change In Other Current Assets |
|
0.02
-96.88%
|
0.54
+10980.00%
|
-0.01
+64.29%
|
-0.01
|
| Change In Other Current Liabilities |
|
-2.29
-306.19%
|
-0.56
+43.84%
|
-1.01
+4.10%
|
-1.05
|
| Investing Cash Flow |
|
-0.14
+11.54%
|
-0.16
+44.09%
|
-0.28
+86.64%
|
-2.09
|
| Cash Flow From Continuing Investing Activities |
|
-0.14
+11.54%
|
-0.16
+44.09%
|
-0.28
+86.64%
|
-2.09
|
| Net PPE Purchase And Sale |
|
-0.14
+11.54%
|
-0.16
+44.09%
|
-0.28
+86.64%
|
-2.09
|
| Purchase Of PPE |
|
-0.21
-33.33%
|
-0.16
+44.09%
|
-0.28
+86.64%
|
-2.09
|
| Sale Of PPE |
|
0.07
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-0.21
-33.33%
|
-0.16
+44.09%
|
-0.28
+86.64%
|
-2.09
|
| Gain Loss On Sale Of Business |
|
—
|
0.00
-100.00%
|
0.26
|
—
|
| Financing Cash Flow |
|
173.35
+0.96%
|
171.71
+408.83%
|
33.75
-10.31%
|
37.63
|
| Cash Flow From Continuing Financing Activities |
|
173.35
+0.96%
|
171.71
+408.83%
|
33.75
-10.31%
|
37.63
|
| Net Issuance Payments Of Debt |
|
-0.49
-2.95%
|
-0.47
+4.81%
|
-0.50
-26.97%
|
-0.39
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
-0.49
-2.95%
|
-0.47
+4.81%
|
-0.50
-26.97%
|
-0.39
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
-0.49
-2.95%
|
-0.47
+4.81%
|
-0.50
-26.97%
|
-0.39
|
| Net Long Term Debt Issuance |
|
-0.49
-2.95%
|
-0.47
+4.81%
|
-0.50
-26.97%
|
-0.39
|
| Net Common Stock Issuance |
|
173.10
+82.98%
|
94.60
+177.22%
|
34.12
|
—
|
| Proceeds From Stock Option Exercised |
|
1.23
-24.20%
|
1.62
+1242.15%
|
0.12
+2925.00%
|
0.00
|
| Net Other Financing Charges |
|
-0.48
-100.64%
|
75.97
|
—
|
—
|
| Changes In Cash |
|
113.14
+0.59%
|
112.48
+1659.38%
|
-7.21
-191.27%
|
7.90
|
| Effect Of Exchange Rate Changes |
|
-0.10
-1087.50%
|
-0.01
-150.00%
|
0.02
|
—
|
| Beginning Cash Position |
|
141.83
+383.12%
|
29.36
-19.69%
|
36.55
+27.58%
|
28.65
|
| End Cash Position |
|
254.87
+79.71%
|
141.83
+383.12%
|
29.36
-19.69%
|
36.55
|
| Free Cash Flow |
|
-60.29
-1.77%
|
-59.24
-44.62%
|
-40.96
-37.80%
|
-29.73
|
| Interest Paid Supplemental Data |
|
0.06
-41.12%
|
0.11
-29.61%
|
0.15
+5.56%
|
0.14
|
| Common Stock Issuance |
|
173.10
+82.98%
|
94.60
+177.22%
|
34.12
|
—
|
| Issuance Of Capital Stock |
|
173.10
+82.98%
|
94.60
+177.22%
|
34.12
-10.24%
|
38.02
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
38.02
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
38.02
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-04-03 View
- 42026-03-09 View
- 42026-03-09 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 8-K2026-02-26 View
- 10-K2026-02-26 View
- 8-K2026-02-24 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-11 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|